Research & Development

Are VA Hospitals in Crisis Due to DOGE Budget Cuts and Firings?
Research & Development Are VA Hospitals in Crisis Due to DOGE Budget Cuts and Firings?

Ivan Kairatov is a Biopharma expert with a wealth of knowledge in tech and innovation within the industry, bolstered by extensive experience in research and development. Today's interview will delve into the impact of recent administrative changes on VA hospitals, specifically examining the

FDA Grants Orphan Drug Designation to Bexmarilimab for MDS Treatment
Research & Development FDA Grants Orphan Drug Designation to Bexmarilimab for MDS Treatment

On March 3, 2025, Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focusing on targeting the CLEVER-1 receptor to reprogram myeloid cells for anti-tumor immunity in both hematological and solid tumors, announced a significant milestone. Their lead therapeutic candidate,

New Cancer Drugs Show Potential to Surpass Keytruda in Clinical Trials
Research & Development New Cancer Drugs Show Potential to Surpass Keytruda in Clinical Trials

The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs c

TFE3 Activation Offers Promising Therapeutic Approach for Parkinson's Disease
Research & Development TFE3 Activation Offers Promising Therapeutic Approach for Parkinson's Disease

Parkinson's disease, a devastating neurodegenerative disorder, is characterized by the relentless loss of dopaminergic neurons, which leads to significant motor dysfunction and a decline in overall quality of life. Central to the pathology of PD are aggregates of alpha-synuclein protein and

Manchester Launches New Center for Cutting-Edge Heart Disease Research
Research & Development Manchester Launches New Center for Cutting-Edge Heart Disease Research

The University of Manchester recently celebrated a significant milestone with the launch of the British Heart Foundation (BHF) Manchester Center of Research Excellence. Supported by a substantial £4 million grant from the BHF, this new center is set to advance world-class cardiovascular research

Protagonist and Takeda's Rusfertide Shows Promise in Phase 3 Trial
Research & Development Protagonist and Takeda's Rusfertide Shows Promise in Phase 3 Trial

The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later